Telavancin
- Generic Name
- Telavancin
- Brand Names
- Vibativ
- Drug Type
- Small Molecule
- Chemical Formula
- C80H106Cl2N11O27P
- CAS Number
- 372151-71-8
- Unique Ingredient Identifier
- XK134822Z0
- Background
Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
- Indication
用于治疗革兰阳性菌耐甲氧西林金黄色葡萄球菌（MRSA）与甲氧西林敏感金黄色葡萄球菌引起的成人复杂性皮肤和皮肤结构感染，以及医院获得性和呼吸机相关细菌性肺炎(HABP/VABP)。
- Associated Conditions
- Bacterial Infections, Nosocomial Pneumonia, Ventilator Associated Bacterial Pneumonia (VABP), Complicated Skin and subcutaneous tissue bacterial infection
- Associated Therapies
- -
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
- Conditions
- Interventions
- First Posted Date
- 2005-04-12
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 1035
- Registration Number
- NCT00107978
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Dept of Med/ER Med, New Orleans, Louisiana, United States
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
- Conditions
- Interventions
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 862
- Registration Number
- NCT00091819
- Locations
- 🇺🇸
Paradise Valley Hospital, 2400 E. 4th Street, National City, California, United States
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
- Conditions
- Interventions
- First Posted Date
- 2004-02-13
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT00077675
- Locations
- 🇺🇸
Paradise Valley Hospital, 2400 E. 4th Street, National City, California, United States
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00062647
- Locations
- 🇺🇸
Wellstar Infectious Disease, Marietta, Georgia, United States
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
- Conditions
- Interventions
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 169
- Registration Number
- NCT00061633
- Locations
- 🇺🇸
eStudy Site, 3450 Bonita Road, Ste 201, Chula Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.